ARDS (Aridis Pharmaceuticals) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 05, 2026)


ARDS Aridis Pharmaceuticals Inc ARDS
12 GF Score
Price $0.00
View Full Analysis

What is Aridis Pharmaceuticals 5-Year Yield-on-Cost %?

Aridis Pharmaceuticals ARDS -99.00% 12 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus rates ARDS with a GF Score™ of 12/100.

Aridis Pharmaceuticals's yield on cost for the quarter that ended in Sep. 2023 was 0.00.


The historical rank and industry rank for Aridis Pharmaceuticals's 5-Year Yield-on-Cost % or its related term are showing as below:



ARDS's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.64
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Aridis Pharmaceuticals  (OTCPK:ARDS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Aridis Pharmaceuticals 5-Year Yield-on-Cost % Related Terms

ARDS vs ARTL, REVB, FWBI: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Aridis Pharmaceuticals's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aridis Pharmaceuticals 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aridis Pharmaceuticals's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Aridis Pharmaceuticals's 5-Year Yield-on-Cost % falls into.


ARDS
12GF Score
Aridis Pharmaceuticals Inc ARDS
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aridis Pharmaceuticals 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Aridis Pharmaceuticals is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Aridis Pharmaceuticals (ARDS) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 05, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aridis Pharmaceuticals and its competitors.
Is Aridis Pharmaceuticals' 5-Year Yield-on-Cost % too high?
Aridis Pharmaceuticals' current 5-Year Yield-on-Cost % is 0.00. Overall, Aridis Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Aridis Pharmaceuticals' 5-Year Yield-on-Cost % compare to ARTL and REVB?
Aridis Pharmaceuticals' 5-Year Yield-on-Cost % of 0.00 can be compared against companies in the Biotechnology industry. The industry median 5-Year Yield-on-Cost % is 1.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.64, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Aridis Pharmaceuticals and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aridis Pharmaceuticals's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aridis Pharmaceuticals stock overvalued right now?
Aridis Pharmaceuticals (ARDS) has a current 5-Year Yield-on-Cost % of 0.00. The current 5-Year Yield-on-Cost % is 0.00. Aridis Pharmaceuticals' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Aridis Pharmaceuticals (ARDS), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aridis Pharmaceuticals Business Description

Address 983 University Avenue, Building B, Los Gatos, CA, USA, 95032
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections.
12GF Score

Get the complete analysis for ARDS

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price